Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Dealing With Rejection: An Application of the Exit-Voice Framework to Genome-Edited Food.

Bartkowski B, Baum CM.

Front Bioeng Biotechnol. 2019 Mar 22;7:57. doi: 10.3389/fbioe.2019.00057. eCollection 2019.

2.

Influence of Environmental Factors on Social Participation Post-Stroke.

Foley EL, Nicholas ML, Baum CM, Connor LT.

Behav Neurol. 2019 Jan 16;2019:2606039. doi: 10.1155/2019/2606039. eCollection 2019.

3.

Initial psychometric evaluation of the Community Participation Activation Scale.

Lee D, Mallinson T, Baum CM, Hammel J.

Can J Occup Ther. 2018 Nov 9:8417418795297. doi: 10.1177/0008417418795297. [Epub ahead of print]

PMID:
30411634
4.

Construct validity of the NIH Toolbox Cognition Battery in individuals with stroke.

Carlozzi NE, Tulsky DS, Wolf TJ, Goodnight S, Heaton RK, Casaletto KB, Wong AWK, Baum CM, Gershon RC, Heinemann AW.

Rehabil Psychol. 2017 Nov;62(4):443-454. doi: 10.1037/rep0000195.

5.

Activity Disengagement: Understanding Challenges and Opportunities for Reengagement.

Fox K, Morrow-Howell N, Herbers S, Battista P, Baum CM.

Occup Ther Int. 2017 Jan 12;2017:1983414. doi: 10.1155/2017/1983414. eCollection 2017.

6.

The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.

Gumbiner B, Joh T, Liang H, Wan H, Levisetti M, Vana AM, Shelton DL, Forgues P, Billotte S, Pons J, Baum CM, Garzone PD.

Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12309. Epub 2017 Nov 23.

PMID:
29078037
7.

Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.

Fazio S, Robertson DG, Joh T, Wan H, Riel T, Forgues P, Baum CM, Garzone PD, Gumbiner B.

Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12308. Epub 2017 Nov 25.

PMID:
29057618
8.

Racial Differences in Neurocognitive Outcomes Post-Stroke: The Impact of Healthcare Variables.

Johnson NX, Marquine MJ, Flores I, Umlauf A, Baum CM, Wong AWK, Young AC, Manly JJ, Heinemann AW, Magasi S, Heaton RK.

J Int Neuropsychol Soc. 2017 Sep;23(8):640-652. doi: 10.1017/S1355617717000480. Epub 2017 Jun 29.

9.

Validation of the NIH Toolbox in Individuals with Neurologic Disorders.

Carlozzi NE, Goodnight S, Casaletto KB, Goldsmith A, Heaton RK, Wong AWK, Baum CM, Gershon R, Heinemann AW, Tulsky DS.

Arch Clin Neuropsychol. 2017 Aug 1;32(5):555-573. doi: 10.1093/arclin/acx020.

10.

Validation of the Participation Strategies Self-Efficacy Scale (PS-SES).

Lee D, Fogg L, Baum CM, Wolf TJ, Hammel J.

Disabil Rehabil. 2018 Jan;40(1):110-115. doi: 10.1080/09638288.2016.1242172. Epub 2016 Oct 28.

PMID:
27793074
11.

Validation and clinical utility of the executive function performance test in persons with traumatic brain injury.

Baum CM, Wolf TJ, Wong AWK, Chen CH, Walker K, Young AC, Carlozzi NE, Tulsky DS, Heaton RK, Heinemann AW.

Neuropsychol Rehabil. 2017 Jul;27(5):603-617. doi: 10.1080/09602011.2016.1176934. Epub 2016 May 6.

PMID:
27150506
12.

The Development of the Improving Participation after Stroke Self-Management Program (IPASS): An Exploratory Randomized Clinical Study.

Wolf TJ, Baum CM, Lee D, Hammel J.

Top Stroke Rehabil. 2016 Aug;23(4):284-92. doi: 10.1080/10749357.2016.1155278. Epub 2016 Mar 16.

13.

Driving Errors in Persons with Dementia.

Barco PP, Baum CM, Ott BR, Ice S, Johnson A, Wallendorf M, Carr DB.

J Am Geriatr Soc. 2015 Jul;63(7):1373-80. doi: 10.1111/jgs.13508. Epub 2015 Jul 3.

PMID:
26140521
14.

Patient Active Time During Therapy Sessions in Postacute Rehabilitation: Development and Validation of a New Measure.

Host HH, Lang CE, Hildebrand MW, Zou D, Binder EF, Baum CM, Freedland KE, Morrow-Howell N, Lenze EJ.

Phys Occup Ther Geriatr. 2014 Jun;32(2):169-178.

15.

Multiple Errands Test-Revised (MET-R): a performance-based measure of executive function in people with mild cerebrovascular accident.

Morrison MT, Giles GM, Ryan JD, Baum CM, Dromerick AW, Polatajko HJ, Edwards DF.

Am J Occup Ther. 2013 Jul-Aug;67(4):460-8. doi: 10.5014/ajot.2013.007880. Erratum in: Am J Occup Ther. 2013 Sep-Oct;67(5):498.

16.

Enhanced medical rehabilitation is feasible in a skilled nursing facility: preliminary data on a novel treatment for older adults with depression.

Lenze EJ, Host HH, Hildebrand M, Morrow-Howell N, Carpenter B, Freedland KE, Baum CM, Binder EF.

Am J Geriatr Psychiatry. 2013 Mar;21(3):307. doi: 10.1016/j.jagp.2012.11.006. Epub 2013 Jan 11. No abstract available.

PMID:
23395198
17.

Pilot randomized controlled trial investigating cognitive strategy use to improve goal performance after stroke.

Polatajko HJ, McEwen SE, Ryan JD, Baum CM.

Am J Occup Ther. 2012 Jan-Feb;66(1):104-9.

PMID:
22389945
18.

Measuring treatment fidelity in a rehabilitation intervention study.

Hildebrand MW, Host HH, Binder EF, Carpenter B, Freedland KE, Morrow-Howell N, Baum CM, Doré P, Lenze EJ.

Am J Phys Med Rehabil. 2012 Aug;91(8):715-24. doi: 10.1097/PHM.0b013e31824ad462.

19.

Modifying health outcome measures for people with aphasia.

Tucker FM, Edwards DF, Mathews LK, Baum CM, Connor LT.

Am J Occup Ther. 2012 Jan-Feb;66(1):42-50. doi: 10.5014/ajot.2012.001255.

PMID:
22251830
20.

Analysis of Cognitive Environmental Support (ACES): preliminary testing.

Ryan JD, Polatajko HJ, McEwen S, Peressotti M, Young A, Rummel K, Farrow S, Villate C, Tracy Morrison M, Baum CM.

Neuropsychol Rehabil. 2011 Jun;21(3):401-27. doi: 10.1080/09602011.2011.572692.

PMID:
21557132
21.

Cognitive approach to improving participation after stroke: two case studies.

Henshaw E, Polatajko H, McEwen S, Ryan JD, Baum CM.

Am J Occup Ther. 2011 Jan-Feb;65(1):55-63.

PMID:
21309372
22.

Fulfilling the promise: supporting participation in daily life.

Baum CM.

Arch Phys Med Rehabil. 2011 Feb;92(2):169-75. doi: 10.1016/j.apmr.2010.12.010.

PMID:
21272711
23.

Mild impairment of cognition impacts on activity participation after stroke in a community-dwelling Australian cohort.

Spitzer J, Tse T, Baum CM, Carey LM.

OTJR (Thorofare N J). 2011 Winter;31(1):S8-S15. doi: 10.3928/15394492-20101108-03.

PMID:
24650267
24.

Introduction to the special issue on cognition and executive function.

Baum CM, Katz N.

OTJR (Thorofare N J). 2011 Winter;31(1):S2. doi: 10.3928/15394492-20101108-01. No abstract available.

PMID:
24650259
25.

A pilot study of activity-based therapy in the arm motor recovery post stroke: a randomized controlled trial.

Janes WE, Wolf TJ, Baum CM.

Clin Rehabil. 2010 Jun;24(6):574-5. doi: 10.1177/0269215510367968. No abstract available.

PMID:
20511304
26.

Effect of upper extremity nerve damage on activity participation, pain, depression, and quality of life.

Bailey R, Kaskutas V, Fox I, Baum CM, Mackinnon SE.

J Hand Surg Am. 2009 Nov;34(9):1682-8. doi: 10.1016/j.jhsa.2009.07.002.

PMID:
19896011
27.

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.

Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD.

Clin Cancer Res. 2009 Sep 15;15(18):5869-77. doi: 10.1158/1078-0432.CCR-08-2480. Epub 2009 Sep 8.

28.

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG.

Clin Cancer Res. 2009 Sep 15;15(18):5902-9. doi: 10.1158/1078-0432.CCR-09-0482. Epub 2009 Sep 8.

29.

Cognitive Functional Evaluation (CFE) Process for Individuals with Suspected Cognitive Disabilities.

Hartman-Maeir A, Katz N, Baum CM.

Occup Ther Health Care. 2009;23(1):1-23. doi: 10.1080/07380570802455516.

PMID:
23930828
30.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.

J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.

31.

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW.

Cancer. 2008 Oct 1;113(7):1552-8. doi: 10.1002/cncr.23776.

32.

Reliability, validity, and clinical utility of the Executive Function Performance Test: a measure of executive function in a sample of people with stroke.

Baum CM, Connor LT, Morrison T, Hahn M, Dromerick AW, Edwards DF.

Am J Occup Ther. 2008 Jul-Aug;62(4):446-55.

PMID:
18712007
33.

Activity of sunitinib in patients with advanced neuroendocrine tumors.

Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS.

J Clin Oncol. 2008 Jul 10;26(20):3403-10. doi: 10.1200/JCO.2007.15.9020.

PMID:
18612155
34.

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD.

J Clin Oncol. 2008 Apr 10;26(11):1810-6. doi: 10.1200/JCO.2007.14.5375. Epub 2008 Mar 17.

PMID:
18347007
35.

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.

Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ.

J Transl Med. 2007 Jul 2;5:32.

36.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA.

N Engl J Med. 2007 Jan 11;356(2):115-24.

37.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.

Lancet. 2006 Oct 14;368(9544):1329-38.

PMID:
17046465
38.

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.

JAMA. 2006 Jun 7;295(21):2516-24.

PMID:
16757724
39.

Screening patients with stroke for rehabilitation needs: validation of the post-stroke rehabilitation guidelines.

Edwards DF, Hahn MG, Baum CM, Perlmutter MS, Sheedy C, Dromerick AW.

Neurorehabil Neural Repair. 2006 Mar;20(1):42-8.

PMID:
16467277
40.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI.

J Clin Oncol. 2006 Jan 1;24(1):16-24. Epub 2005 Dec 5.

PMID:
16330672
41.
42.

Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy.

Radcliff FJ, Caruso DA, Koina C, Riordan MJ, Roberts AW, Tang ML, Baum CM, Woulfe SL, Ashley DM.

Br J Haematol. 2002 Oct;119(1):204-11.

PMID:
12358927
43.

Clinical-scale production of granulocyte progenitor and post-progenitor cells using daniplestim, leridistim, Progenipoietin, Promegapoietin and autologous plasma.

Patel SD, Guo R, Miller WM, Papoutsakis ET, Minster NI, Baum CM, Winter JN.

Cytotherapy. 2000;2(2):85-94. Erratum in: Cytotherapy. 2000;2(5):405..

PMID:
12042045
44.

Mobilization of peripheral-blood stem cells by concurrent administration of daniplestim and granulocyte colony-stimulating factor in patients with breast cancer or lymphoma.

DiPersio JF, Schuster MW, Abboud CN, Winter JN, Santos VR, Collins DM, Sherman JW, Baum CM.

J Clin Oncol. 2000 Jul;18(14):2762-71.

PMID:
10894877
45.

Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34(+) cells.

Scheding S, Meister B, Bühring HJ, Baum CM, Mc Kearn JP, Bock T, Kanz L, Brugger W.

Exp Hematol. 2000 Apr;28(4):460-70.

PMID:
10781904
46.

Effective ex vivo generation of megakaryocytic cells from mobilized peripheral blood CD34(+) cells with stem cell factor and promegapoietin.

Kratz-Albers K, Scheding S, Möhle R, Bühring HJ, Baum CM, Mc Kearn JP, Büchner T, Kanz L, Brugger W.

Exp Hematol. 2000 Mar;28(3):335-46.

PMID:
10720698
48.

Home-based multidisciplinary diagnosis and treatment of inner-city elders with dementia.

Edwards DF, Baum CM, Meisel M, Depke M, Williams J, Braford T, Morrow-Howell N, Morris JC.

Gerontologist. 1999 Aug;39(4):483-8.

PMID:
10495587
49.

Occupational therapy practice: focusing on occupational performance.

Baum CM, Law M.

Am J Occup Ther. 1997 Apr;51(4):277-88. Review. Erratum in: Am J Occup Ther 1997 Jul-Aug;51(7):604.

PMID:
9085726
50.

Supplemental Content

Support Center